130 related articles for article (PubMed ID: 35449318)
21. Network-based approach to identify prognosis-related genes in tamoxifen-treated patients with estrogen receptor-positive breast cancer.
Wang Y; Gong X; Zhang Y
Biosci Rep; 2021 Sep; 41(9):. PubMed ID: 34406386
[TBL] [Abstract][Full Text] [Related]
22. NR4A1 Regulates Tamoxifen Resistance by Suppressing ERK Signaling in ER-Positive Breast Cancer.
Kim YC; Kim CY; Oh JH; Kim MH
Cells; 2021 Jun; 10(7):. PubMed ID: 34209871
[TBL] [Abstract][Full Text] [Related]
23. Long Non-Coding RNA (lncRNA) 91H Confers Tamoxifen Resistance in ER+ Breast Cancer Cells through Inhibiting mTOR Signaling Pathway.
Lv ZY; Mo QP; Tang HC; Zheng SS
Ann Clin Lab Sci; 2022 Nov; 52(6):947-955. PubMed ID: 36564063
[TBL] [Abstract][Full Text] [Related]
24. Downregulated lncRNA ADAMTS9-AS2 in breast cancer enhances tamoxifen resistance by activating microRNA-130a-5p.
Shi YF; Lu H; Wang HB
Eur Rev Med Pharmacol Sci; 2019 Feb; 23(4):1563-1573. PubMed ID: 30840279
[TBL] [Abstract][Full Text] [Related]
25. Linc-RoR promotes MAPK/ERK signaling and confers estrogen-independent growth of breast cancer.
Peng WX; Huang JG; Yang L; Gong AH; Mo YY
Mol Cancer; 2017 Oct; 16(1):161. PubMed ID: 29041978
[TBL] [Abstract][Full Text] [Related]
26. During hormone depletion or tamoxifen treatment of breast cancer cells the estrogen receptor apoprotein supports cell cycling through the retinoic acid receptor α1 apoprotein.
Salazar MD; Ratnam M; Patki M; Kisovic I; Trumbly R; Iman M; Ratnam M
Breast Cancer Res; 2011 Feb; 13(1):R18. PubMed ID: 21299862
[TBL] [Abstract][Full Text] [Related]
27. Long Non-Coding RNA (lncRNA) Urothelial Carcinoma-Associated 1 (UCA1) Enhances Tamoxifen Resistance in Breast Cancer Cells via Inhibiting mTOR Signaling Pathway.
Wu C; Luo J
Med Sci Monit; 2016 Oct; 22():3860-3867. PubMed ID: 27765938
[TBL] [Abstract][Full Text] [Related]
28. Polycomb complex protein BMI1 confers resistance to tamoxifen in estrogen receptor positive breast cancer.
Ojo D; Lin X; Wu Y; Cockburn J; Bane A; Tang D
Cancer Lett; 2018 Jul; 426():4-13. PubMed ID: 29626519
[TBL] [Abstract][Full Text] [Related]
29. Long non-coding RNA UCA1 enhances tamoxifen resistance in breast cancer cells through a miR-18a-HIF1α feedback regulatory loop.
Li X; Wu Y; Liu A; Tang X
Tumour Biol; 2016 Nov; 37(11):14733-14743. PubMed ID: 27629141
[TBL] [Abstract][Full Text] [Related]
30. Role of RBP2-Induced ER and IGF1R-ErbB Signaling in Tamoxifen Resistance in Breast Cancer.
Choi HJ; Joo HS; Won HY; Min KW; Kim HY; Son T; Oh YH; Lee JY; Kong G
J Natl Cancer Inst; 2018 Apr; 110(4):. PubMed ID: 29028222
[TBL] [Abstract][Full Text] [Related]
31.
Fang Z; Wang Y; Wang Z; Xu M; Ren S; Yang D; Hong M; Xie W
Cancer Res; 2020 Oct; 80(20):4399-4413. PubMed ID: 32826278
[TBL] [Abstract][Full Text] [Related]
32. AFF3 upregulation mediates tamoxifen resistance in breast cancers.
Shi Y; Zhao Y; Zhang Y; AiErken N; Shao N; Ye R; Lin Y; Wang S
J Exp Clin Cancer Res; 2018 Oct; 37(1):254. PubMed ID: 30326937
[TBL] [Abstract][Full Text] [Related]
33. Estrogen-regulated AGR3 activates the estrogen receptor signaling pathway to promote tamoxifen resistance in breast cancer.
Jiang R; Sun Y; Chen X; Shi P
Breast Cancer Res Treat; 2021 Nov; 190(2):203-211. PubMed ID: 34519905
[TBL] [Abstract][Full Text] [Related]
34. Fatostatin in Combination with Tamoxifen Induces Synergistic Inhibition in ER-Positive Breast Cancer.
Liu Y; Zhang N; Zhang H; Wang L; Duan Y; Wang X; Chen T; Liang Y; Li Y; Song X; Li C; Han D; Chen B; Zhao W; Yang Q
Drug Des Devel Ther; 2020; 14():3535-3545. PubMed ID: 32921987
[TBL] [Abstract][Full Text] [Related]
35. The Wnt signalling pathway is upregulated in an in vitro model of acquired tamoxifen resistant breast cancer.
Loh YN; Hedditch EL; Baker LA; Jary E; Ward RL; Ford CE
BMC Cancer; 2013 Apr; 13():174. PubMed ID: 23547709
[TBL] [Abstract][Full Text] [Related]
36. Loss of B-cell translocation gene 2 expression in estrogen receptor-positive breast cancer predicts tamoxifen resistance.
Takahashi M; Hayashida T; Okazaki H; Miyao K; Jinno H; Kitagawa Y
Cancer Sci; 2014 Jun; 105(6):675-82. PubMed ID: 24698107
[TBL] [Abstract][Full Text] [Related]
37. Long noncoding RNA DLGAP1-AS2 facilitates Wnt1 transcription through physically interacting with Six3 and drives the malignancy of gastric cancer.
Lu J; Xu Y; Xie W; Tang Y; Zhang H; Wang B; Mao J; Rui T; Jiang P; Zhang W
Cell Death Discov; 2021 Sep; 7(1):255. PubMed ID: 34545072
[TBL] [Abstract][Full Text] [Related]
38. The long noncoding RNA H19 promotes tamoxifen resistance in breast cancer via autophagy.
Wang J; Xie S; Yang J; Xiong H; Jia Y; Zhou Y; Chen Y; Ying X; Chen C; Ye C; Wang L; Zhou J
J Hematol Oncol; 2019 Jul; 12(1):81. PubMed ID: 31340867
[TBL] [Abstract][Full Text] [Related]
39. LncRNA DILA1 inhibits Cyclin D1 degradation and contributes to tamoxifen resistance in breast cancer.
Shi Q; Li Y; Li S; Jin L; Lai H; Wu Y; Cai Z; Zhu M; Li Q; Li Y; Wang J; Liu Y; Wu Z; Song E; Liu Q
Nat Commun; 2020 Nov; 11(1):5513. PubMed ID: 33139730
[TBL] [Abstract][Full Text] [Related]
40. Long non-coding RNA LPP-AS2 promotes glioma tumorigenesis via miR-7-5p/EGFR/PI3K/AKT/c-MYC feedback loop.
Zhang X; Niu W; Mu M; Hu S; Niu C
J Exp Clin Cancer Res; 2020 Sep; 39(1):196. PubMed ID: 32962742
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
